Wire · regulatory
FDA's new GenAi draft framework: Risk assessments and extended responsibility
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 August 2026 · Fusion42 review
The FDA has released a discussion paper outlining a potential framework for regulating generative AI-enabled medical devices, focusing on risk assessments, performance evaluation, and post-market monitoring, while soliciting feedback on unresolved questions.
This Wire brief sits within Fusion42's coverage of Medtech, and 14 sources have reported it between 18 Aug 2026 and 15 Sep 2026.
◆ ◆ The Wire takeaway
FDA's early GenAI framework signals regulatory expectations shaping fast. Medtech founders should prepare to adapt product development and compliance ahead of formal rules.
◆ Coverage
14 sources · first reported 18 Aug 2026 · latest 15 Sep 2026
◆ Related on Wire
◆ Topics